In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

Aptar Pharma’s Ready-to-Use Program Facilitates Development Times
Publications, Pharmaceutical, Innovation & Insights, Product Solutions

Good Medicine: Solutions for Sensitive Injectable Formulations
Webinars, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Market Insights, Product Solutions

Connected Medicine: Insights from Payers and Other Stakeholders
Publications, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Brand Differentiation, Product Solutions

Pharma Partnering Considerations for Injectable Device Components
Publications, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Product Solutions